Running head: Maternal serum nicotinamide and offspring atopic eczema.

**Higher maternal serum concentrations of nicotinamide and related metabolites in late pregnancy are associated with a lower risk of offspring atopic eczema at age 12 months**

El-Heis S1, Crozier SR1, Robinson SM1,2, Harvey NC1,2, Cooper C1,2,4, Inskip HM1,2, Southampton Women’s Survey Study Group, Godfrey KM1,2,3

1 Medical Research Council Lifecourse Epidemiology Unit, University of Southampton, UK.

2 NIHR Nutrition Biomedical Research Centre, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton, UK

3 Institute of Developmental Sciences, University of Southampton, Southampton, UK

4 NIHR Musculoskeletal Biomedical Research Unit, University of Oxford, Oxford, UK.

Correspondence to:

Professor Keith Godfrey

Medical Research Council Lifecourse Epidemiology Unit (University of Southampton)

Southampton General Hospital, Mail point 95

Southampton SO16 6YD

United Kingdom.

Tel: 44 (0)23 80777624

Fax: +44 (0)23 80704021

Email: kmg@mrc.soton.ac.uk

Key words: Atopic eczema, maternal micronutrients, nicotinamide.

Word count: 1956

**Abstract**

Background: Evidence that atopic eczema partly originates in utero is increasing, with some studies linking the risk of developing the condition with aspects of maternal diet during pregnancy. Nicotinamide, a naturally occurring nutrient that is maintained through the dietary intakes of vitamin B3 and tryptophan has been used in the treatment of some skin conditions including atopic eczema.

Objective: To examine the relation of maternal serum concentrations of nicotinamide and related tryptophan metabolites to the risk of atopic eczema in the offspring.

Methods: Within the UK Southampton Women Survey, infantile atopic eczema at ages 6 and 12 months was ascertained (modified UK Working Party Criteria for the Definition of Atopic Dermatitis). Maternal serum levels of kynurenine, kynurenic acid, anthranilic acid, tryptophan, nicotinamide and N1-methylnicotinamide were measured in late pregnancy by mass spectrometry, n=497 and related to the odds ratio of infantile atopic eczema.

Results: Maternal nicotinamide and related metabolite concentrations were not associated with offspring atopic eczema at age 6 months. Higher concentrations of nicotinamide and anthranilic acid were, however, associated with a lower risk of eczema at age 12 months (odds ratios 0.69, 95% CI 0.53-0.91 /SD change, p=0.007 and 0.63, 0.48-0.83, p=0.001, respectively). The associations were robust to adjustment for potentially confounding variables.

Conclusion and clinical relevance: This is the first study linking maternal serum concentrations of nicotinamide and related metabolites to the risk of atopic eczema in the offspring. The findings point to potentially modifiable maternal influences on this complex and highly prevalent condition.

**Introduction**

Atopic eczema is a highly prevalent and complex condition and evidence that it partly originates in utero is increasing. The risk of developing atopic eczema has been linked with a variety of environmental factors in pregnancy, including mother’s age, education and smoking, and some studies have proposed links with aspects of maternal diet during pregnancy. [1]

Nicotinamide is the amide form of niacin, also known as vitamin B3, an essential vitamin. Both compounds are precursors of nicotinamide adenine dinucleotide (NAD) and nicotinamide adenine dinucleotide phosphate (NADP) in vivo. Nicotinamide is maintained by the intake of vitamin B3, found in foods including fish, meat, chicken, mushrooms, nuts and coffee, and by the intake of tryptophan, an essential amino acid that is a constituent of most proteins and is the precursor for serotonin and melatonin. In the liver, tryptophan can be converted to niacin via the kynurenine pathway, with quinolone acids as key intermediates.

The kynurenine pathway (Figure 1) is the major route for tryptophan metabolism in mammals, and is reported to regulate several fundamental biological processes, including cell death. Activation of the tryptophan catabolizing enzyme indoleamine 2,3-dioxygenase, induced by inflammatory stimuli (most importantly interferon-γ), leads to the formation of kynurenine and other metabolites that counter-regulate immune activation; in chronic immune activation continued immunosuppressive feedback mechanisms lead to elevated kynurenine concentrations. Kynurenine has been reported to enhance IgE-mediated responses. [2] Tryptophan is metabolised through kynureninase and kynurenine transaminase. Kynureninase converts kynurenine to anthranilic acid (AA) and 3-hydroxykynurenine (HK) to 3-hydroxyanthranilic acid (3-HAA). Kynurenine transaminase converts the same two substrates into kynurenic acid (KA) and xanthurenic acid (XA), respectively. 3HAA is further converted to acroleyl aminofumarate, which in turn is converted to quinolinic acid (QA) through non enzymatic cyclization before conversion to nicotinic acid (niacin), the precursor for NAD. 3HAA and QA can alter Th1 cells [3], thus tending to increase Th2 reactivity. N1-Methylnicotinamide is a metabolite of nicotinamide; produced primarily in the liver, it has anti-inflammatory properties and may also influence thrombosis through activation of prostacyclin activation. [4]

In a randomised control trial, topical 2% nicotinamide applied twice a day to atopic eczema for 4 and 8 weeks significantly reduced water loss and increased stratum corneum hydration when compared with white petrolatum. [5] Orally, nicotinamide has been shown to reduce transepidermal water loss. [6] It is not fully understood how oral nicotinamide administration may alter cellular inflammation in vivo; in a limited group of healthy human participants exposed to experimental endotoxaemia it had little effect on cytokines or exhaled nitric oxide. [7]

The above observations led us to examine the hypothesis that higher maternal serum concentrations of nicotinamide and related tryptophan metabolites in late pregnancy may be associated with a decreased risk of atopic eczema in the offspring.

**Methods**

Within the UK Southampton Women’s Survey (SWS), a mother-offspring study, information on maternal diet, lifestyle and socioeconomic status was collected. [8] Women were followed up through their pregnancies, 3008 delivered a live born infant with no major congenital growth abnormalities and were assessed for atopic eczema at 6 or 12 months. Of these, 497 had an aliquot available for measurement of serum tryptophan, kynurenine, kynurenic acid, anthranilic acid, nicotinamide and N1-Methylnicotinamide concentrations in late pregnancy. Fragmentation confirmed the identity of the analytes. Measurements were made by (BEVITAL AS, Norway) using liquid chromatography–mass spectrometry/mass spectrometry [9]; coefficients of variation were <12%.

Case definition of atopic eczema was based on the UK Working Party diagnostic criteria for the definition of atopic eczema [10], assessed by trained research nurses who undertook a standardised questionnaire and examination. A personal history of atopy was omitted as a criterion given the young age of the infants, who were not old enough to have developed clearly defined asthma or hay fever.

Metabolite concentrations were transformed using Fisher-Yates transformation [11] to allow analysis of relations per standard deviation (SD) change in concentration. Univariate and multivariate logistic regression analyses were performed (Stata version 13.0, Statacorp LP, TX) to relate maternal demographic and lifestyle characteristics, maternal serum metabolite levels and early life factors to infant eczema at ages 6 and 12 months. Maternal factors that were considered as potential confounders were: age at child’s birth, pre-pregnancy BMI, education, smoking, parity and maternal history of eczema in creases of elbows or knees in the last 12 months (at 6 months); potential infant confounders were: sex, gestational age, birth weight, breastfeeding duration and filaggrin single-nucleotide polymorphism rs7512552 (identified as related to atopic eczema in the SWS cohort as part of the replication studies following a recent multi-ancestry genome-wide association study [12], and available for 414 infants in this subsample).

All phases of the Southampton Women’s Survey were approved by the Southampton and South West Hampshire Local Research Ethics Committee and parents gave written informed consent.

**Results**

Maternal and infant characteristics are summarised in Table 1. Among the 497 participants, the mother’s average age at child’s birth was 31.2 years (Standard Deviation (SD) = 3.5); 48.9% were primiparous and 12.5% smoked during pregnancy. 50.7% of infants were male; mean birthweight of infants was 3.51 kg (SD 0.47) and gestational age 40.1 weeks (IQR 39.1 – 41.0). 30.6% of the infants had the rs 7512552 SNP. 10.7% and 13.7% had atopic eczema at ages 6 and 12 months, respectively.

Supplementary Table 1 shows that the characteristics of the 497 participants in the study group with maternal metabolite measurements in late pregnancy were similar to the overall SWS cohort. However, the study group mothers were older at child’s birth, smoking was less prevalent and infants’ birthweight was higher.

Table 2 shows univariate analyses of maternal and infant characteristics in relation to infant atopic eczema at age 6 months. Girls had a lower odds ratio of atopic eczema at age 6 months (p=0.002). None of the maternal serum metabolite concentrations were associated with offspring atopic eczema at age 6 months. However, univariate analyses of maternal and infant characteristics showed that higher maternal serum concentrations of nicotinamide and anthranilic acid were associated with lower odds ratios of atopic eczema at age 12 months (Table 3; nicotinamide OR 0.70, 95%CI 0.53-0.90 per SD change, p=0.007, Figure 2a; anthranilic acid OR 0.63, 95%CI 0.48-0.83 per SD change, p=0.001, Figure 2b). No significant associations were found with late pregnancy serum levels of tryptophan, kynurenine, kynurenic acid or N1-methylnicotinamide. Higher maternal pre-pregnancy BMI (p=0.001) and male sex (p=0.009) were also associated with higher odds ratios of atopic eczema at age 12 months.

As concentrations of nicotinamide and anthranilic acid showed a significant correlation (r=0.218,p<0.001), we undertook separate multivariate analyses of each metabolite in relation to atopic eczema, taking account of maternal characteristics and other potential confounding variables (Table 4). Taking account of these other variables, higher maternal serum nicotinamide (p=0.013) and anthranilic acid (p=0.003) concentrations remained significantly associated with lower risks of atopic eczema at age 12 months. The odds ratios and P values changed little after additionally taking account of rs 7512552 SNP, available for a subsample of the group (data not shown).

**Discussion**

Our results show that maternal nicotinamide and related tryptophan metabolite concentrations were not associated with offspring atopic eczema at 6 months. However, higher late pregnancy maternal concentrations of nicotinamide and anthranilic acid were associated with a lower prevalence of eczema at age 12 months. These associations were resistant to adjustment for potential confounding variables.

Nicotinamide is the precursor of NAD and is the sole substrate and an inhibitor of the nuclear enzyme poly-ADP-ribose polymerase 1 (PARP-1). [13] Through these functions, nicotinamide can enhance energy-dependent cellular processes such as DNA repair [14], and maintain genomic stability and regulation of some transcription factors, particularly in relation to the expression of inflammatory cytokines, chemokines, adhesion molecules and inflammatory mediators. [15] Nicotinamide inhibits cyclic adenosine monophosphate phosphodiesterase (cAMP PDE) and stabilises mast cells and leukocytes through inhibition of histamine and immunoglobulin E release. [16] It has also been shown to increase the biosynthesis of ceramide and other stratum corneum lipids [17] and prevents the upregulation of aquaporin, thereby decreasing water permeability and water loss. [18] Nicotinamide can improve the overall structure, moisture, and elasticity of skin as it increases the synthesis of collagen and proteins that play an important role in the formation of keratin, filaggrin, and involucrin. [19] Through these functions, nicotinamide has the potential to alter the disease processes associated with atopic eczema.

There is only limited evidence of an effect of dietary factors on serum tryptophan metabolite concentrations. Dietary niacin is readily converted to nicotinamide in the body and challenge studies have shown a robust rise in anthranilic acid concentrations after administration of sodium benzoate, a widely used preservative found in many foods and soft drinks. [20] These observations suggest that influences other than intakes of niacin and tryptophan may underlie the associations we found.

As can be inferred from Figure 1, lower levels of anthranilic acid and nicotinamide do not point to a specific enzymatic block in the tryptophan pathway either genetically or environmentally induced, and lower levels of these two metabolites may be a general reflection of perturbation of the pathway or low substrate availability. Additionally, our findings (Figure 2) show a graded association between lower maternal nicotinamide and anthranilic acid levels and the offspring’s risk of atopic eczema, pointing away from a simple genetically determined enzymatic block. However, the pathway has not been intensively investigated and we hope our data will stimulate more intensive investigation including analysis of genetic polymorphisms.

Although total tryptophan is decrease in the third trimester of pregnancy [21], free tryptophan is increased due to decreased binding to albumin, as albumin decreases and non-esterified fatty acids increase in late pregnancy. [22] Nicotinamide is able to cross the human placenta, and fetal blood levels of nicotinamide are greater than corresponding maternal blood levels. [23] There are no reports of adverse effects due to nicotinamide in human fetuses, but the effect of high doses is unknown. [23] There is no human data on maternal use of B vitamins and tryptophan in relation to offspring atopic eczema, however, animal studies on long-term high dose nicotinamide supplementation in pregnancy, have been associated with nicotinamide-induced oxidative tissue injury, insulin resistance and disturbed methyl metabolism that can lead to epigenetic changes. [24]

Our study highlights a link between lower maternal nicotinamide levels and related tryptophan metabolites and an increased risk of atopic eczema in the offspring. Strengths of the study are its prospective nature, the standardised assessment of eczema by trained staff and control for confounding factors. Limitations of our study were the relatively small sample size of 497 and the lack of measurements of metabolite levels in early pregnancy. Replicating the findings in other populations would be a valuable next step. Modified UK Working Party Diagnostic Criteria for Atopic Dermatitis were used, in which we omitted atopic disease in a first degree relative as we are seeking to disentangle the apparent heterogeneous phenotypes that ‘atopic eczema’ is now thought to represent; excluding those with no family history of atopy would remove an important group of infants from such studies. This modification has, however, not previously been validated. Maternal late pregnancy concentrations of nicotinamide and anthranilic acid were associated with infant eczema at age 12 months but not at age 6 months; this could also reflect heterogeneity in the etiology and pathogenesis of atopic eczema in early childhood. [25] Although the association was independent of filaggrin status, no information was available on methylation quantitative trait loci that may also influence tryptophan metabolism.

In summary, our study is the first to link maternal serum levels of nicotinamide and related metabolites to the risk of atopic eczema in the offspring. The findings point to potentially modifiable maternal influences on this complex, multifactorial condition and support the evidence that atopic eczema partly originates in utero.

**Funding**

This work was supported by grants from the Medical Research Council, British Heart Foundation, Food Standards Agency, Arthritis Research UK, National Osteoporosis Society, International Osteoporosis Foundation, Cohen Trust, European Union's Seventh Framework (FP7/2007-2013), projects EarlyNutrition and ODIN under grant agreement numbers 289346 and 613977, NIHR Southampton Biomedical Research Centre, University of Southampton and University Hospital Southampton NHS Foundation Trust, NIHR Musculoskeletal Biomedical Research Unit, University of Oxford and British Lung Foundation.

**Author contributions**

The authors’ responsibilities were as follows—KMG, HMI, SMR, and CC: were responsible for the design and conduct of the Southampton Women's Survey; SEH and KMG: planned the analyses and drafted the manuscript; SEH: conducted the statistical analyses with support from SRC; and all authors: read and approved the final version of the manuscript.

**Conflict of interest**

KMG has received reimbursement for speaking at conferences sponsored by companies selling nutritional products and is part of an academic consortium that has received research funding from Abbott Nutrition, Nestec, and Danone. No other author reports any potential conflicts of interest.

**References**

1. Beckhaus AA, Garcia-Marcos L, Forno E, Pacheco-Gonzalez RM, Celedón JC, Castro-Rodriguez JA. Maternal nutrition during pregnancy and risk of asthma, wheeze, and atopic diseases during childhood: a systematic review and meta-analysis. *Allergy* 2015; 70:1588-1604.
2. Kawasaki H, Chang HW, Tseng HC, Hsu SC, Yang SJ, Hung CH, et al. A tryptophan metabolite, kynurenine, promotes mast cell activation through aryl hydrocarbon receptor. *Allergy* 2014; 69:445-52.
3. Fallarino F, Grohmann U, Vacca C, Bianchi R, Orabona C,Spreca A, et al. T cell apoptosis by tryptophan catabolism. *Cell Death Differ* 2002; 9:1069–1077.
4. Gebicki J, Sysa-Jedrzejowska A, Adamus J, Woźniacka A, Rybak M, Zielonka J. 1-Methylnicotinamide: a potent anti-inflammatory agent of vitamin origin. *Pol J Pharmaco*l 2003; 55:109-12
5. Soma Y, Kashima M, Imaizumi A, Takahama H, Kawakami T, Mizoguchi M. Moisturizing effects of topical nicotinamide on atopic dry skin. *Int J Dermatol* 2005; 44:197–202.
6. Chen AC, Martin AJ, Dalziell RA, Halliday GM, Damian DL.Oral nicotinamide reduces transepidermal water loss: a randomised controlled trial. *Br J Dermatol* 2016 – Epub Apr 7.
7. Soop A, Albert J, Weitzberg E, Bengtsson A, Nilsson CG, Sollevi A.Nicotinamide does not influence cytokines or exhaled NO in human experimental endotoxaemia. *Clin Exp Immunol* 2004; 135:114-8.
8. Inskip HM, Godfrey KM, Robinson SM, Law CM, Barker DJ, Cooper C; SWS Study Group. Cohort profile: The Southampton Women's Survey*. Int J Epidemiol* 2006; 35:42-48.
9. Midttun Ø, Hustad S, Ueland PM. Quantitative profiling of biomarkers related to B-vitamin status, tryptophan metabolism and inflammation in human plasma by liquid chromatography/tandem mass spectrometry. *Rapid Commun Mass Spectrom* 2009; 23:1371-9.
10. Williams HC, Burney PG, Pembroke AC, Hay RJ. The U.K. Working Party's Diagnostic Criteria for Atopic Dermatitis. III. Independent hospital validation. *Br J Dermatol* 1994; 131:406-16.
11. Armitage P, Berry G. Statistical Methods in Medical Research. Third Edition. Oxford, United Kingdom: Blackwell Science Ltd, 2002.
12. Paternoster L, Standl M, Waage J, Baurecht H, Hotze M, Strachan DP, Curtin JA, The EArly Genetics and Lifecourse Epidemiology (EAGLE) Eczema Consortium. Multi-ancestry genome-wide association study of 21,000 cases and 95,000 controls identifies new risk loci for atopic dermatitis. *Nat Genet* 2015; 47:1449-56
13. Jacobson EL, Shieh WM, Huang AC. Mapping the role of NAD metabolism in prevention and treatment of carcinogenesis. *Mol Cell Biol* 1999; 193:69–74.
14. Surjana D, Halliday GM, Damian DL. Role of nicotinamide in DNA damage, mutagenesis, and DNA repair. *J. Nucleic Acids* 2010; 2010:157591.
15. Virag L, Szabo C. The therapeutic potential of poly (ADP-ribose) polymerase inhibitors. *Pharmacol Rev* 2002; 54:375–429.
16. Namazi MR. Nicotinamide as a potential addition to the anti-atopic dermatitis armamentarium. *Int Immunopharmacol* 2004; 4:709–12.
17. Tanno O, Ota Y, Kitamura N, Katsube T, Inoue S. Nicotinamide increases biosynthesis of ceramides as well as other stratum corneum lipids to improve the epidermal permeability barrier. *Br J Dermatol* 2000; 143:524–31
18. Song X, Xu A, Pan W, Wallin B, Kivlin R, Lu S, et al. Nicotinamide attenuates aquaporin 3 overexpression induced by retinoic acid through inhibition of EGFR/ERK in cultured human skin keratinocytes. *Int J Mol Med* 2008; 22:229–36
19. Bissett DL, Oblong JE, Saud A, Berge CA, Trejo AV, Beidermann KA. Topical niacinamide provides skin aging appearance benefits while enhancing skin barrier function. *J Clin Dermatol* 2003; 32:S9–18.
20. Lennerz BS, Vafai SB, Delaney NF, Clish CB, Deik AA, Pierce KA, et al. Effects of sodium benzoate, a widely used food preservative, on glucose homeostasis and metabolic profiles in humans. *Mol Genet Metab* 2015; 114:73-9.
21. Luan H, Meng N, Liu P, Feng Q, Lin S, Fu J, et al. Pregnancy-induced metabolic phenotype variations in maternal plasma. J Proteome Res 2014; 13:1527-36
22. Badawy AA. Tryptophan metabolism, disposition and utilization in pregnancy. Biosci Rep 2015; 35: 1-16.
23. Stockton DL, Paller AS. Drug administration to the pregnant or lactating woman: a reference guide for dermatologists. *J Am Acad Dermatol* 1990; 23: 87–103.
24. Li D, Tian YJ, Guo J, Sun WP, Lun YZ, Guo M, et al. Nicotinamide supplementation induces detrimental metabolic and epigenetic changes in developing rats. *Br J Nutr* 2013; 110: 2156–64.
25. Loo EX, Shek LP, Goh A, Teoh OH, Chan YH, Soh SE, et al. Atopic Dermatitis in Early Life: Evidence for at Least Three Phenotypes? Results from the GUSTO Study. *Int Arch Allergy Immunol* 2015; 166: 273-9.

Table 1. Characteristics of the study population

|  |  |  |
| --- | --- | --- |
|  | n | Median (IQR), Mean (SD) or n (%) |
| *Maternal*  |  |  |
| Age at child’s birth (years) | 497 | 31.2 (3.5) |
| Pre-pregnancy BMI (kg/m2) | 493 | 24.2 (22.2- 27.2) |
| A level or higher education  | 311 | 62.8%  |
| Smoking in pregnancy  | 497 | 62 (12.5%) |
| Primiparous | 243 | 48.9%  |
| Eczema in the last 12 months  | 270 | 9.4% |
| Duration of gestation at late pregnancy blood sample (weeks) | 492 | 34.5 (0.6) |
| Maternal serum metabolite concentrations in late pregnancy (n = 497)Tryptophan (µmol/L)Kynurenine (µmol/L)Kynurenic acid (nmol/L)Anthranilic acid (nmol/L)Nicotinamide (nmol/L)N1- Methylnicotinamide (nmol/L) | 497497497497497497 | 55.5 (49.1-62.8)1.2 (1.1-1.4)21.9 (17.0-27.6)14.5 (12.1- 16.9)140.2 (81.1-213.6)246.2 (164.4-368.1) |
| *Infant* |  |  |
| Male | 252 | 50.7% |
| Gestational age (weeks) | 497 | 40.1 (39.1- 41.0) |
| Birthweight (kg) | 494 | 3.51 (0.47) |
| SNP (rs7512552) | 414 | 30.6%  |
| Breast feeding (completed months)Never breast fed  <1 1 to 34 to 6 7 to 1112 or more *6 month assessment*  | 74 9586948645 | 15.4%19.8%17.9%19.6%17.9%9.4% |
| Age (weeks) | 495 | 26.7 (25.9 – 27.6) |
| Weight (kg) | 494 | 7.99 (0.94) |
| Atopic eczema as per UK Working Party criteria  | 53 | 10.7% |
| *12 month assessment* |  |  |
| Age (weeks) | 467 | 53.6 (52.4 – 54.6) |
| Weight (kg) | 465 | 10.12(1.1) |
| Atopic eczema as per UK Working Party criteria | 64 | 13.7% |

Table 2. Univariate analyses of maternal and infant characteristics as predictors of atopic eczema at age 6 months.

|  |
| --- |
|  |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| *Maternal characteristics*  |  |  |  |  |
| Age (years) | 495 | 1.01 | 0.93 – 1.10 | 0.76  |
| Pre-pregnancy BMI (SD) | 491 | 1.29 | 0.99 – 1.68 | 0.06  |
| Education (6 levels) | 493 | 0.99 | 0.80 – 1.23 | 0.95 |
| Smoking in pregnancy (no/yes) | 495 | 0.70 | 0.27 – 1.84 | 0.47 |
| Parity (0/ 1+) | 495 | 0.65 | 0.36 – 1.15 | 0.14 |
| Eczema in last 12 months (no/yes) | 492 | 1.98 | 0.83-4.75 | 0.13 |
| *Maternal serum metabolite concentrations in late pregnancy*  |  |  |  |  |
| Tryptophan (SD) | 495 | 1.05  | 0.79 - 1.40 | 0.73  |
| Kynurenine (SD) | 495 | 1.04  | 0.78 -1.38 | 0.80  |
| Kynurenic acid (SD) | 495 | 1.25  | 0.93 - 1.67 | 0.14 |
| Anthranilic acid (SD) | 495 | 0.85  | 0.63 - 1.13 | 0.26  |
| Nicotinamide (SD) | 495 | 0.94  | 0.71 - 1.26 | 0.70  |
| N1-Methylnicotinamide (SD) | 495 | 0.92  | 0.69 - 1.23 | 0.57  |
| *Infant characteristics* |  |  |  |  |
| Sex (male=1/ female=2) | 495 | 0.37  | 0.20 - 0.69 | 0.002  |
| Gestational age (weeks) | 495 | 0.99 | 0.80 – 1.22 | 0.93  |
| Birth weight (kg) | 492 | 1.30 | 0.71-2.36 | 0.40 |
| Breast feeding (6 groups) | 480 | 1.02 | 0.85 – 1.22 | 0.86 |
| SNP rs7512552 (no/yes) | 413 | 0.70 | 0.46-1.09 | 0.11 |
|  |  |  |  |  |

n OR 95%CI p-value

SD: standard deviation

Table 3. Univariate analyses of maternal and infant characteristics as predictors of atopic eczema at age 12 months.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | n | OR  | 95% CI | p-value |
| *Maternal characteristics*  |  |  |  |  |
| Age (years) | 467 | 0.96 | 0.89 -1.03 | 0.27 |
| Pre-pregnancy BMI (SD) | 463 | 1.49 | 1.17-1.92 | 0.001 |
| Education (6 levels) | 465 | 0.85 | 0.69-1.04 | 0.12 |
| Smoking (no/yes) | 467 | 1.67 | 0.83-3.34 | 0.15 |
| Parity (0/ 1+) | 467 | 0.71 | 0.42-1.20 | 0.20 |
| Eczema in the last 12 months (no/yes) | 464 | 1.28 | 0.51-3.20 | 0.60 |
| *Maternal serum metabolite concentrations in late pregnancy* |  |  |  |  |
| Tryptophan (SD) | 467 | 1.03 | 0.79 - 1.34 | 0.84  |
| Kynurenine (SD) | 467 | 0.90 | 0.69 - 1.18 | 0.47  |
| Kynurenic acid (SD) | 467 | 1.03  | 0.79 - 1.35 | 0.80  |
| Anthranilic acid (SD) | 467 | 0.63  | 0.48 - 0.83 | 0.001  |
| Nicotinamide (SD) | 467 | 0.70  | 0.53 - 0.90 | 0.007  |
| N1-Methylnicotinamide (SD) | 467 | 0.78  | 0.59 - 1.01 | 0.06  |
| *Infant characteristics* |  |  |  |  |
| Sex (male=1/ female=2) | 467 | 0.48 | 0.28 - 0.84 | 0.009  |
| Gestational age (weeks) | 467 | 0.95 | 0.79-1.16 | 0.64 |
| Birth weight (kg) | 464 | 0.78 | 0.44-1.37 | 0.38 |
| Breast feeding (6 groups) | 457 | 0.92 | 0.78- 1.09 | 0.36 |
|  SNP rs7512552 (no/yes) | 387 | 0.80 | 0.54-1.18 | 0.26 |
|  |  |  |  |  |

SD: Standard deviation

Table 4. Multivariate analysis of maternal and infant characteristics as predictors of atopic eczema at age 12 months, including a) serum nicotinamide, b) serum anthranilic acid levels in late pregnancy (n = 467)

|  |  |  |  |
| --- | --- | --- | --- |
|  | OR | CI | P-value  |

|  |  |  |  |
| --- | --- | --- | --- |
| (a) |  |  |  |
| *Maternal*   Serum nicotinamide (SD)Maternal age (years)Pre-pregnancy BMI(kg/m2)Maternal education (6 groups)Smoking in pregnancy (no/yes)Parity (0/ 1+)Eczema (no/yes) | 0.701.011.070.831.390.621.28 | 0.52-0.930.93 - 1.091.01 - 1.130.65 - 1.060.64 - 3.040.35 - 1.110.49-3.34 | 0.0130.860.020.140.410.140.62 |
| *Infant*Sex (male=1/ female=2)Gestational age (weeks)Breast feeding duration (6 groups) | 0.480.970.99 | 0.27 - 0.860.79 - 1.190.81 - 1.22 | 0.0140.740.95 |

|  |  |  |  |
| --- | --- | --- | --- |
| (b) |  |  |  |
| *Maternal* Serum anthranilic acid (SD)Maternal age (years)Pre-pregnancy BMI(kg/m2)Maternal education (6 groups)Smoking in pregnancy (no/ yes)Parity (0/ 1+)Eczema (no/yes) | 0.641.001.070.86 1.12 0.62 1.09  | 0.48 – 0.86 0.92 - 1.091.02 - 1.14 0.68 - 1.10 0.51 - 2.460.35 - 1.100.41 - 2.92 | 0.0030.980.0130.24 0.79 0.110.86 |
| *Infant*Sex (male=1/ female=2)Gestational age (weeks)Breast feeding duration (6 groups) | 0.47 0.96 0.96  | 0.26 - 0.840.78 - 1.180.78 - 1.17 | 0.011 0.70 0.67  |

Maternal education groups (1= none, 2= SCE , 3= O level (Ordinary Level General Certificate of Education), 4= A level (General Certificate of Education Advanced Level), 5= HND (Higher National Diploma), 6= Degree).

Breast feeding duration groups (completed months (1= Never tried, 2= <1, 3= 1-3, 4= 4-6, 5= 7-11, 6= 12 or more)).

\*Controlling for mother’s age at child’s birth, BMI, smoking, educational attainment and parity and child’s sex, gestational age and breast feeding diration +/- SE

**Referent**

***P=0.014 for linear trend of continuous variable***

**Highest**

**3rd**

**2nd**

**Lowest**

**Quarter of the distribution of maternal**

**serum nicotinamide at 34 weeks gestation**

**Odds ratio**

**of atopic**

**eczema\***